Chemed (NYSE:CHE) released its earnings results on Wednesday. The company reported $2.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.05, Bloomberg Earnings reports. Chemed had a net margin of 8.49% and a return on equity of 30.54%. The company had revenue of $428.35 million for the quarter, compared to the consensus estimate of $423.83 million. During the same quarter in the previous year, the company earned $2.10 EPS. Chemed’s quarterly revenue was up 6.2% compared to the same quarter last year. Chemed updated its FY18 guidance to $10.60-10.85 EPS.
Shares of Chemed (CHE) traded up $4.35 during trading hours on Wednesday, reaching $253.73. 140,326 shares of the company’s stock were exchanged, compared to its average volume of 97,507. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48. The company has a market capitalization of $4,033.49, a price-to-earnings ratio of 56.38 and a beta of 1.13. Chemed has a 12-month low of $170.54 and a 12-month high of $275.83.
Several research analysts have weighed in on CHE shares. Royal Bank of Canada upped their target price on shares of Chemed to $232.00 and gave the stock a “sector perform” rating in a research note on Tuesday, October 31st. KeyCorp reiterated a “hold” rating on shares of Chemed in a research note on Friday, October 27th. TheStreet upgraded shares of Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Zacks Investment Research upgraded shares of Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price for the company in a research note on Thursday, November 2nd. Finally, ValuEngine lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $236.00.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.